LONDON, United Kingdom (AP) — The European Union’s drug regulatory agency said Thursday that the AstraZeneca vaccine doesn’t increase the overall incidence of blood clots and that the benefits of using it outweigh the possible risks, paving the way for European countries to resume dispensing the shots.

France and Italy promptly announced they will start using the vaccine again on Friday. Other countries were expected to follow suit.

More than a dozen nations around the world, including Germany and Spain, had suspended their use of the vaccine over the past week following reports of clots in a few dozen of the millions of people across Europe who have gotten the shot. The question was whether the vaccine had anything to do with the clots.

The safety committee of the European Medicines Agency “has come to a clear scientific conclusion,” announced the head of the EMA, Emer Cooke. “This is a safe and effective vaccine.”

She added: “If it were me, I would be vaccinated tomorrow.”

However, she said the agency “still cannot rule out definitively a link” between certain rare types of blood clots and the vaccine. The EMA recommended adding a description of these cases to the vaccine leaflets.